Does the media favor CAI or MTD?

In the previous week, Mettler-Toledo International had 4 more articles in the media than Caris Life Sciences. MarketBeat recorded 8 mentions for Mettler-Toledo International and 4 mentions for Caris Life Sciences. Caris Life Sciences' average media sentiment score of 0.12 beat Mettler-Toledo International's score of 0.11 indicating that Caris Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Caris Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mettler-Toledo International 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, CAI or MEDP?

Medpace has higher revenue and earnings than Caris Life Sciences. Medpace is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Caris Life Sciences $812.03M 9.43 -$68.09M $0.36 75.28 Medpace $2.53B 6.67 $451.12M $17.06 35.42

Does the media favor CAI or MEDP?

In the previous week, Medpace had 12 more articles in the media than Caris Life Sciences. MarketBeat recorded 16 mentions for Medpace and 4 mentions for Caris Life Sciences. Medpace's average media sentiment score of 0.51 beat Caris Life Sciences' score of 0.12 indicating that Medpace is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Caris Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Medpace 5 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, CAI or RVTY?

Revvity has higher revenue and earnings than Caris Life Sciences. Revvity is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Caris Life Sciences $812.03M 9.43 -$68.09M $0.36 75.28 Revvity $2.86B 5.99 $241.20M $2.10 73.06

Does the media prefer CAI or RVTY?

In the previous week, Revvity had 8 more articles in the media than Caris Life Sciences. MarketBeat recorded 12 mentions for Revvity and 4 mentions for Caris Life Sciences. Revvity's average media sentiment score of 0.46 beat Caris Life Sciences' score of 0.12 indicating that Revvity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Caris Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Revvity 3 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, ICLR or CAI?

Icon has higher revenue and earnings than Caris Life Sciences. Icon is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Icon $8.25B 1.52 $229.34M $4.26 38.52 Caris Life Sciences $812.03M 9.43 -$68.09M $0.36 75.28

Does the media favor ICLR or CAI?

In the previous week, Caris Life Sciences had 1 more articles in the media than Icon. MarketBeat recorded 4 mentions for Caris Life Sciences and 3 mentions for Icon. Icon's average media sentiment score of 0.67 beat Caris Life Sciences' score of 0.12 indicating that Icon is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Icon 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Caris Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Caris Life Sciences (CAI) Competitors

$27.10 -0.35 (-1.28%)

Closing price 10/7/2026 04:00 PM Eastern

Extended Trading

$26.52 -0.58 (-2.12%)

As of 07:14 AM Eastern

Compare

CAI vs. MTD, MEDP, RVTY, CRL, and ICLR

Should you buy Caris Life Sciences stock or one of its competitors? Caris Life Sciences's main competitors and comparable companies include Mettler-Toledo International (MTD), Medpace (MEDP), Revvity (RVTY), Charles River Laboratories International (CRL), and Icon (ICLR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Caris Life Sciences compare to Mettler-Toledo International?

Caris Life Sciences (NASDAQ:CAI) and Mettler-Toledo International (NYSE:MTD) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

In the previous week, Mettler-Toledo International had 4 more articles in the media than Caris Life Sciences. MarketBeat recorded 8 mentions for Mettler-Toledo International and 4 mentions for Caris Life Sciences. Caris Life Sciences' average media sentiment score of 0.12 beat Mettler-Toledo International's score of 0.11 indicating that Caris Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Caris Life Sciences	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mettler-Toledo International	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Caris Life Sciences has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market. Comparatively, Mettler-Toledo International has a beta of 1.19, indicating that its share price is 19% more volatile than the broader market.

95.1% of Mettler-Toledo International shares are owned by institutional investors. 50.0% of Caris Life Sciences shares are owned by insiders. Comparatively, 0.7% of Mettler-Toledo International shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Caris Life Sciences currently has a consensus price target of $26.50, suggesting a potential downside of 2.21%. Mettler-Toledo International has a consensus price target of $1,459.54, suggesting a potential downside of 4.71%. Given Caris Life Sciences' stronger consensus rating and higher possible upside, research analysts clearly believe Caris Life Sciences is more favorable than Mettler-Toledo International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caris Life Sciences	1 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.46
Mettler-Toledo International	1 Sell rating(s)	9 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.27

Mettler-Toledo International has a net margin of 21.91% compared to Caris Life Sciences' net margin of 10.62%. Caris Life Sciences' return on equity of 18.77% beat Mettler-Toledo International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caris Life Sciences	10.62%	18.77%	9.34%
Mettler-Toledo International	21.91%	-1,212.14%	25.11%

Mettler-Toledo International has higher revenue and earnings than Caris Life Sciences. Mettler-Toledo International is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caris Life Sciences	$812.03M	9.43	-$68.09M	$0.36	75.28
Mettler-Toledo International	$4.03B	7.62	$869.19M	$44.43	34.47

Summary

Caris Life Sciences and Mettler-Toledo International tied by winning 8 of the 16 factors compared between the two stocks.

How does Caris Life Sciences compare to Medpace?

Caris Life Sciences (NASDAQ:CAI) and Medpace (NASDAQ:MEDP) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

Caris Life Sciences presently has a consensus target price of $26.50, suggesting a potential downside of 2.21%. Medpace has a consensus target price of $607.73, suggesting a potential upside of 0.58%. Given Medpace's higher probable upside, analysts plainly believe Medpace is more favorable than Caris Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caris Life Sciences	1 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.46
Medpace	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.23

In the previous week, Medpace had 12 more articles in the media than Caris Life Sciences. MarketBeat recorded 16 mentions for Medpace and 4 mentions for Caris Life Sciences. Medpace's average media sentiment score of 0.51 beat Caris Life Sciences' score of 0.12 indicating that Medpace is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Caris Life Sciences	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Medpace	5 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Medpace has a net margin of 17.67% compared to Caris Life Sciences' net margin of 10.62%. Medpace's return on equity of 110.15% beat Caris Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caris Life Sciences	10.62%	18.77%	9.34%
Medpace	17.67%	110.15%	24.84%

78.0% of Medpace shares are held by institutional investors. 50.0% of Caris Life Sciences shares are held by company insiders. Comparatively, 20.5% of Medpace shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Medpace has higher revenue and earnings than Caris Life Sciences. Medpace is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caris Life Sciences	$812.03M	9.43	-$68.09M	$0.36	75.28
Medpace	$2.53B	6.67	$451.12M	$17.06	35.42

Caris Life Sciences has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market. Comparatively, Medpace has a beta of 1.18, indicating that its share price is 18% more volatile than the broader market.

Summary

Medpace beats Caris Life Sciences on 11 of the 16 factors compared between the two stocks.

How does Caris Life Sciences compare to Revvity?

Caris Life Sciences (NASDAQ:CAI) and Revvity (NYSE:RVTY) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, institutional ownership, earnings, profitability, valuation and risk.

Caris Life Sciences presently has a consensus price target of $26.50, suggesting a potential downside of 2.21%. Revvity has a consensus price target of $120.50, suggesting a potential downside of 21.46%. Given Caris Life Sciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Caris Life Sciences is more favorable than Revvity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caris Life Sciences	1 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.46
Revvity	0 Sell rating(s)	14 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.26

Caris Life Sciences has a net margin of 10.62% compared to Revvity's net margin of 8.16%. Caris Life Sciences' return on equity of 18.77% beat Revvity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caris Life Sciences	10.62%	18.77%	9.34%
Revvity	8.16%	8.34%	5.01%

86.7% of Revvity shares are held by institutional investors. 50.0% of Caris Life Sciences shares are held by insiders. Comparatively, 0.9% of Revvity shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Revvity has higher revenue and earnings than Caris Life Sciences. Revvity is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caris Life Sciences	$812.03M	9.43	-$68.09M	$0.36	75.28
Revvity	$2.86B	5.99	$241.20M	$2.10	73.06

Caris Life Sciences has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market. Comparatively, Revvity has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market.

In the previous week, Revvity had 8 more articles in the media than Caris Life Sciences. MarketBeat recorded 12 mentions for Revvity and 4 mentions for Caris Life Sciences. Revvity's average media sentiment score of 0.46 beat Caris Life Sciences' score of 0.12 indicating that Revvity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Caris Life Sciences	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Revvity	3 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Caris Life Sciences beats Revvity on 9 of the 16 factors compared between the two stocks.

How does Caris Life Sciences compare to Charles River Laboratories International?

Charles River Laboratories International (NYSE:CRL) and Caris Life Sciences (NASDAQ:CAI) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.

Caris Life Sciences has a net margin of 10.62% compared to Charles River Laboratories International's net margin of -5.96%. Caris Life Sciences' return on equity of 18.77% beat Charles River Laboratories International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Charles River Laboratories International	-5.96%	15.75%	6.51%
Caris Life Sciences	10.62%	18.77%	9.34%

Caris Life Sciences has lower revenue, but higher earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Charles River Laboratories International	$4.02B	3.57	-$144.34M	-$4.85	N/A
Caris Life Sciences	$812.03M	9.43	-$68.09M	$0.36	75.28

98.9% of Charles River Laboratories International shares are owned by institutional investors. 1.3% of Charles River Laboratories International shares are owned by company insiders. Comparatively, 50.0% of Caris Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Charles River Laboratories International currently has a consensus price target of $300.11, suggesting a potential downside of 0.03%. Caris Life Sciences has a consensus price target of $26.50, suggesting a potential downside of 2.21%. Given Charles River Laboratories International's stronger consensus rating and higher possible upside, research analysts clearly believe Charles River Laboratories International is more favorable than Caris Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Charles River Laboratories International	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.88
Caris Life Sciences	1 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.46

In the previous week, Charles River Laboratories International had 22 more articles in the media than Caris Life Sciences. MarketBeat recorded 26 mentions for Charles River Laboratories International and 4 mentions for Caris Life Sciences. Charles River Laboratories International's average media sentiment score of 0.73 beat Caris Life Sciences' score of 0.12 indicating that Charles River Laboratories International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Charles River Laboratories International	4 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Caris Life Sciences	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Charles River Laboratories International has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market. Comparatively, Caris Life Sciences has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market.

Summary

Charles River Laboratories International beats Caris Life Sciences on 9 of the 17 factors compared between the two stocks.

How does Caris Life Sciences compare to Icon?

Icon (NASDAQ:ICLR) and Caris Life Sciences (NASDAQ:CAI) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends, media sentiment and analyst recommendations.

95.6% of Icon shares are owned by institutional investors. 44.0% of Icon shares are owned by insiders. Comparatively, 50.0% of Caris Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Caris Life Sciences had 1 more articles in the media than Icon. MarketBeat recorded 4 mentions for Caris Life Sciences and 3 mentions for Icon. Icon's average media sentiment score of 0.67 beat Caris Life Sciences' score of 0.12 indicating that Icon is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Icon	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Caris Life Sciences	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Icon has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market. Comparatively, Caris Life Sciences has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market.

Icon currently has a consensus target price of $172.40, suggesting a potential upside of 5.07%. Caris Life Sciences has a consensus target price of $26.50, suggesting a potential downside of 2.21%. Given Icon's higher possible upside, research analysts clearly believe Icon is more favorable than Caris Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Icon	2 Sell rating(s)	8 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.39
Caris Life Sciences	1 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.46

Caris Life Sciences has a net margin of 10.62% compared to Icon's net margin of 3.99%. Caris Life Sciences' return on equity of 18.77% beat Icon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Icon	3.99%	8.02%	4.56%
Caris Life Sciences	10.62%	18.77%	9.34%

Icon has higher revenue and earnings than Caris Life Sciences. Icon is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Icon	$8.25B	1.52	$229.34M	$4.26	38.52
Caris Life Sciences	$812.03M	9.43	-$68.09M	$0.36	75.28

Summary

Icon and Caris Life Sciences tied by winning 8 of the 16 factors compared between the two stocks.

Get Caris Life Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CAI vs. The Competition

Export

Metric	Caris Life Sciences	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$7.76B	$10.53B	$7.16B	$13.44B
Dividend Yield	N/A	1.44%	2.53%	16.47%
P/E Ratio	75.28	32.02	274.55	26.10
Price / Sales	9.43	106.32	571.53	87.31
Price / Cash	17.22	27.56	77.41	52.81
Price / Book	13.22	6.71	10.79	6.27
Net Income	-$68.09M	$56.67B	$3.50B	$382.03M
7 Day Performance	-4.41%	-0.25%	-0.39%	-0.52%
1 Month Performance	9.19%	7.61%	-6.11%	-4.80%
1 Year Performance	N/A	28.79%	4.15%	-0.71%

Caris Life Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CAI Caris Life Sciences	2.5858 of 5 stars	$27.10 -1.3%	$26.50 -2.2%	N/A	$7.76B	$812.03M	75.28	1,846
MTD Mettler-Toledo International	2.3683 of 5 stars	$1,511.60 -0.5%	$1,446.36 -4.3%	+17.3%	$30.29B	$4.03B	34.02	18,100	Analyst Forecast
MEDP Medpace	2.3849 of 5 stars	$618.88 -0.3%	$595.20 -3.8%	+13.6%	$17.27B	$2.53B	36.28	6,200	Analyst Forecast
RVTY Revvity	3.0839 of 5 stars	$150.84 +0.1%	$116.57 -22.7%	+68.2%	$16.86B	$2.86B	71.83	11,000	Analyst Forecast
CRL Charles River Laboratories International	3.3533 of 5 stars	$292.49 -0.7%	$287.06 -1.9%	+76.5%	$13.98B	$4.02B	N/A	19,700	Trending News Insider Trade Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CAI) was last updated on 10/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Caris Life Sciences (CAI) Competitors

CAI vs. MTD, MEDP, RVTY, CRL, and ICLR

How does Caris Life Sciences compare to Mettler-Toledo International?

Summary

How does Caris Life Sciences compare to Medpace?

Summary

How does Caris Life Sciences compare to Revvity?

Summary

How does Caris Life Sciences compare to Charles River Laboratories International?

Summary

How does Caris Life Sciences compare to Icon?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAI vs. The Competition

Caris Life Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Caris Life Sciences (CAI) Competitors

CAI vs. MTD, MEDP, RVTY, CRL, and ICLR

How does Caris Life Sciences compare to Mettler-Toledo International?

Does the media favor CAI or MTD?

Which has more risk and volatility, CAI or MTD?

Do insiders & institutionals believe in CAI or MTD?

Do analysts rate CAI or MTD?

Is CAI or MTD more profitable?

Which has stronger valuation and earnings, CAI or MTD?

Summary

How does Caris Life Sciences compare to Medpace?

Do analysts rate CAI or MEDP?

Does the media favor CAI or MEDP?

Is CAI or MEDP more profitable?

Do institutionals and insiders believe in CAI or MEDP?

Which has better earnings & valuation, CAI or MEDP?

Which has more risk & volatility, CAI or MEDP?

Summary

How does Caris Life Sciences compare to Revvity?

Do analysts recommend CAI or RVTY?

Is CAI or RVTY more profitable?

Do insiders and institutionals hold more shares of CAI or RVTY?

Which has preferable valuation and earnings, CAI or RVTY?

Which has more risk & volatility, CAI or RVTY?

Does the media prefer CAI or RVTY?

Summary

How does Caris Life Sciences compare to Charles River Laboratories International?

Is CRL or CAI more profitable?

Which has higher earnings & valuation, CRL or CAI?

Do institutionals and insiders hold more shares of CRL or CAI?

Do analysts rate CRL or CAI?

Does the media favor CRL or CAI?

Which has more volatility & risk, CRL or CAI?

Summary

How does Caris Life Sciences compare to Icon?

Do institutionals & insiders hold more shares of ICLR or CAI?

Does the media favor ICLR or CAI?

Which has more risk & volatility, ICLR or CAI?

Do analysts recommend ICLR or CAI?

Is ICLR or CAI more profitable?

Which has higher valuation and earnings, ICLR or CAI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAI vs. The Competition

Caris Life Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools